Autopsy report · NCT04892017

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

“Trial terminated due to business decision, not based on any safety or efficacy concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 4 years 9 months before it stopped.
• 91 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Deciphera Pharmaceuticals, LLC

Sponsor type

Industry

Conditions

Non-Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Solid Tumor

Interventions

Inlexisertib; Trametinib; Binimetinib; Sotorasib

Participants

91

Sites

10

Countries

United States

Trials that died the same way

• A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer
  “The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.” (90% match in meaning)
• A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
  “This trial was terminated voluntarily by the Sponsor for reasons related to its corporate strategic development, with no safety concerns or efficacy signals related to the investigational product identified.” (81% match in meaning)
• A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
  “The trial prematurely terminated due to the inability to recruit the planned number of subjects. The decision to terminate the trial was not based on any safety concerns.” (81% match in meaning)
• Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
  “The trial was terminated early on 05 October 2022 due to non-feasibility and poor recruitment and not based on safety concerns.” (80% match in meaning)
• Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201
  “This study was voluntarily terminated due to a business decision not to proceed, and not due to any safety or efficacy issue.” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.